Humacyte, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Humacyte, Inc. (HUMA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.61M, a 7.15% increase year-over-year.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.17M, a 27.46% increase year-over-year.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.51M, a 61.73% increase year-over-year.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.43M, a 69.38% increase year-over-year.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.41M, a 69.64% increase from fiscal 2024.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.14M, a 10.12% decline from fiscal 2023.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.83M, a 10.41% increase from fiscal 2022.
- Humacyte, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.18M, a 39.05% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.61M 10-Q · filed 2026-08-12 | $5.78M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $3.17M 10-Q · filed 2026-08-12 | |||
| 2025-12-31 | $10.41M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $2.51M 10-Q · filed 2025-11-12 | $4.94M derived: sum of 2 quarters · filed 2026-08-12 | $7.43M derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-06-30 | $2.43M 10-Q · filed 2026-08-12 | $4.92M derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $2.49M 10-Q · filed 2026-08-12 | |||
| 2024-12-31 | $6.14M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $1.55M 10-Q · filed 2025-11-12 | $2.99M derived: sum of 2 quarters · filed 2025-11-12 | $4.44M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.44M 10-Q · filed 2025-11-12 | $2.89M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $1.45M 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $6.83M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $1.77M 10-Q · filed 2024-11-08 | $3.61M derived: sum of 2 quarters · filed 2024-11-08 | $5.42M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $1.84M 10-Q · filed 2024-11-08 | $3.65M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $1.81M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $6.18M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $1.48M 10-Q · filed 2023-11-09 | $2.97M derived: sum of 2 quarters · filed 2023-11-09 | $4.51M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.49M 10-Q · filed 2023-11-09 | $3.04M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $1.55M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $10.15M 10-K · filed 2023-03-24 | |||
| 2021-09-30 | $1.88M 10-Q · filed 2022-11-10 | $4.81M derived: sum of 2 quarters · filed 2022-11-10 | $7.33M derived: sum of 3 quarters · filed 2022-11-10 | |
| 2021-06-30 | $2.93M 10-Q · filed 2022-11-10 | $5.46M derived: sum of 2 quarters · filed 2022-11-10 | ||
| 2021-03-31 | $2.53M 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $4.69M 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $1.17M 10-Q · filed 2021-11-15 | $2.28M derived: sum of 2 quarters · filed 2021-11-15 | $3.47M derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $1.11M 10-Q · filed 2021-11-15 | $2.30M derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $1.18M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |